Soligenix Announces Recent Accomplishments And Year End 2024 Financial Results
On January 14, 2025, the Company reported positive outcomes observed from the interim update on the open-label, investigator-initiated study (IIS) evaluating extended HyBryteTM treatment for up to 12 ...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new ...
Investornewsbreaks Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) Advances Single-Dose Vaccine For Mpox
Tonix Pharmaceuticals (NASDAQ: TNXP) , a biopharmaceutical company developing innovative vaccines, is advancing TNX-801, a live, minimally replicatin ...
Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
August 15, 2025, is the FDA PDUFA goal date for TNX-102 SL for the management of fibromyalgia; If approved, TNX-102 SL would become the first new drug for treating fibromyalgia in more than 15 years ...
Nasdaq3d
Tonix Pharmaceuticals Announces FDA PDUFA Goal Date for TNX-102 SL and Positive Developments Across Pipeline
Tonix Pharmaceuticals Holding Corp. announced that the FDA has set a PDUFA goal date of August 15, 2025, for TNX-102 SL, which, if approved, would be the first new drug for fibromyalgia in over 15 ...
Why Soligenix (NASDAQ: SNGX) Is ‘One to Watch’
Soligenix (NASDAQ: SNGX) is a late-stage biopharmaceutical company focused on developing and commercializing treatments for rare diseases with high unmet medical needs. “Operati ...